Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Invicta Medical

Request full access

Operates as a medical technology company that develops therapies for sleep apnea

San Jose, United StatesFounded 2013Biotech & Life Sciences

About Invicta Medical

Established in 2012, Invicta Medical, which has been rebranded as Restera, is a clinical-stage medical technology firm positioned to address the significant market for sleep apnea therapies. The company was founded by Steven Kent and Hal Kent. Rick O'Connor currently serves as the CEO.

The company is focused on developing treatments for obstructive sleep apnea (OSA), a condition affecting an estimated one billion people worldwide, with a significant number remaining undiagnosed. The economic burden of untreated sleep apnea in the United States alone is estimated at $150 billion annually due to associated health conditions and loss of productivity. Restera targets the shortcomings of existing therapies, such as CPAP machines, which suffer from low patient compliance rates due to their cumbersome and intrusive nature.

Restera's primary offering is an intelligent neurostimulation system, which is described as the world's first and only injectable sleep apnea therapy. This system involves a minimally invasive procedure, taking approximately five to ten minutes, where a small, flexible device is injected near the hypoglossal nerve without scalpels or surgery. The implant stimulates the genioglossus muscle, moving the tongue forward to keep the airway open during sleep. The platform includes options for a traditional implantable power source or a wireless, fully injectable device without an onboard battery. This approach allows for the treatment of a broad range of patients, including those with a high BMI or different types of airway collapse.

The company has a strong intellectual property portfolio with 35 patents and patents pending. Clinical data from six studies involving 65 patients has demonstrated a significant reduction in the Apnea-Hypopnea Index (AHI) on the first night of therapy, a notable improvement over existing treatments. To date, Invicta Medical has raised a total of $73.3 million over five funding rounds, with the latest being a Series C round of $25 million in April 2023. The company is seeking further funding to complete feasibility studies and aim for a commercial launch.

Source: Dealroom company data

At a glance

Status
Operational
Employees
8
Open positions
None listed
Dealroom signal
60.3/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing May 2024 $0 — MedTech Innovator ↗
LATE VC✓Equity / VC Oct 2022 $18M $105M Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Invicta Medical website traffic

Latest recorded traffic for Invicta Medical is 2.5K monthly website visits, up 635.3% over the last three months. Invicta Medical's team declined 27.3% over the past year.

Latest monthly visits2.5K 3-month web change+635.3% 1-year team growth-27.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Invicta Medical in the San Jose ecosystem

Live from Dealroom

The Invicta Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • R Ventures

Series A4 investors entered at this stage

Other known investors5 additional known investors

  • MedTech Innovator
  • DNS Capital
  • Grayson Judge
  • Mike Masterson
  • Robin Farmanfarmaian
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States66.7%
🇸🇪 Sweden33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Invicta Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Invicta Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.